AstraZeneca (AZ) has announced that its immunotherapy Imfinzi (durvalumab) has been approved by the European Commission (EC) ...

The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

IMFINZITM (durvalumab) has received approval in the European Union as a monotherapy for treating adults with limited-stage ...

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

AstraZeneca (AZN) said Friday it plans to invest $2.5 billion in a new research and development hub in China as the drugmaker tries to reignite ...

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development ...

Independent Advisor Alliance increased its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.0% in the fourth ...

Astra will buy EsoBiotec for up to £770m comprised of an initial £327m payment and another £443m in the future if it hits ...

The United Kingdom's stock market has recently faced challenges, with the FTSE 100 index slipping due to weak trade data from China, highlighting concerns over global economic recovery. In this ...

BEIJING] AstraZeneca will invest US$2.5 billion in a new research centre in Beijing, in a major show of commitment to China ...